CMBA
NBIX icon

C.M. Bidwell & Associates’s Neurocrine Biosciences NBIX Stock Holding History

C.M. Bidwell & Associates’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-894
Closed -$118K – 528
2023
Q4 		$118K Buy
894
+5
+0.6% +$576 0.09% 147
2023
Q3 		$100K Buy
+889
New +$93.6K 0.08% 230
2023
Q1 		– Sell
-419
Closed -$50K – 544
2022
Q4 		$50K Hold
419
– – 0.04% 288
2022
Q3 		$45K Buy
+419
New +$42.5K 0.04% 279
2018
Q4 		– Sell
-275
Closed -$34K – 441
2018
Q3 		$34K Buy
+275
New +$31.2K 0.03% 257

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

C.M. Bidwell & Associates's NBIX Position: Q1 2024 in Review

C.M. Bidwell & Associates sold out of Neurocrine Biosciences (NBIX) in Q1 2024, closing a stake of 894 shares — an estimated $118K sold.

C.M. Bidwell & Associates first reported a position in NBIX in Q3 2018 and held it in 5 quarters. The position peaked at $118K in Q4 2023. 589 funds tracked by Wall St. Rank hold NBIX as of Q1 2024.

  • C.M. Bidwell & Associates reported no remaining Neurocrine Biosciences position as of Q1 2024 after selling out during the quarter.
  • C.M. Bidwell & Associates sold 894 Neurocrine Biosciences shares in Q1 2024, an estimated $118K.
  • C.M. Bidwell & Associates first reported a position in Neurocrine Biosciences in Q3 2018 and held it in 5 quarters.
  • C.M. Bidwell & Associates's Neurocrine Biosciences position peaked at $118K in Q4 2023.
  • 589 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2024.

Based on C.M. Bidwell & Associates's 13F filing for Q1 2024, filed 14 May 2024.